Byondis Seeks Partner For Lead ADC To Enter Crowded Breast Cancer Market
Positive Top-Line Results From TULIP Study
Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.
You may also be interested in...
The drug may see a muted launch given the competitive landscape and a broad label despite its efficacy advantage in F-allele patients.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Europe’s strengths in the biotech space include world-class science, but the continent needs to build on its strengths in order to deliver on the promise of a coming “golden age” of biotech, says a recent report.